TheraRadar
Data updated: Jun 28, 2026

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (calcium chloride) · VANTIVE US HLTHCARE

Renal Approved 1978-09-27

DIANEAL PD-2 with Dextrose is a peritoneal dialysis solution indicated for the management of patients with acute or chronic renal failure. It is administered intraperitoneally to remove metabolic waste products and toxic substances from the body and to assist in the regulation of fluid and electrolyte balance when kidney function is inadequate.

How DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER Works

DIANEAL PD-2 functions through the processes of diffusion and osmosis across the peritoneal membrane. Dextrose in the solution creates an osmotic gradient that draws excess water (ultrafiltrate) from the patient's plasma into the peritoneal cavity. Simultaneously, metabolic waste products (such as urea and creatinine) and electrolytes move along concentration gradients between the capillary blood and the dialysis solution. This allows for the clearance of toxins and the correction of electrolyte imbalances. Sodium, chloride, calcium, and magnesium are included to maintain or normalize plasma levels, while lactate serves as a bicarbonate precursor to correct metabolic acidosis.

2
Indications
--
Phase 3 Trials
47
Years on Market

Details

Status
Prescription
First Approved
1978-09-27
Routes
INTRAPERITONEAL
Dosage Forms
SOLUTION

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER Approval History

1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
120 FDA actions from 1978 to 2023
Jun 2023 SUPPL
Label · Labeling
Dec 2016 SUPPL
Mfg · Manufacturing (CMC)
Aug 2016 SUPPL
Label · Labeling

What DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER Treats

2 indications

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER is approved for 2 conditions since its original approval in 1978. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

Drugs Similar to DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

3 of 19

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
CALCIUM CHLORIDE
2 shared
Pfizer
CARDIOPLEGIC IN PLASTIC CONTAINER
CALCIUM CHLORIDE
2 shared
Baxter
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER
CALCIUM CHLORIDE
2 shared
Fresenius Kabi
📋

Clinical Trial Registry

7 trials
Trial Sponsor ID Phase Status Title
NCT07550413 20042026 Ph 2 not yet recruiting Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section
NCT03772990 ICARUS 21/2019 Ph 4 completed Calcium Administration in Cardiac Surgery
NCT05027048 CALBLOC results posted 62206 MRTG-02-15-2022-Ansari, YIG-2020 Ph 3 completed Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
NCT04153435 COCA results posted 00002 2019-003387-46 Ph 2 completed Calcium for Out-of-Hospital Cardiac Arrest
NCT03867383 results posted 43076 Ph 1, Ph 2 completed Calcium Chloride for Prevention of Uterine Atony During Cesarean
NCT01941914 AA1310 Ph 1 completed Calcium Electroporation for the Treatment of Keloids
NCT00955266 results posted 2009-P-000052 Ph 4 terminated A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

Ringer’s Injection is indicated for use as a source of water and electrolytes in adults and pediatric patients. Ringer’s Injection is indicated for use as a source of water and electrolytes in adults and pediatric patients.

Track DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.